Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Among HIV-Negative Participants Using Tenofovir/Emtricitabine-Based Preexposure Prophylaxis in 2020: A Substudy of the French National Agency for Research on AIDS and Viral Hepatitis PREVENIR and Inserm SAPRIS-Sero Cohorts

The potential preventive efficacy of tenofovir/emtricitabine on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was assessed in human immunodeficiency virus preexposure prophylaxis (PrEP) users. Prevalence of SARS-CoV-2 immunoglobulin G between May and October 2020 was similar...

Descripción completa

Detalles Bibliográficos
Autores principales: Delaugerre, Constance, Assoumou, Lambert, Maylin, Sarah, Minier, Marine, Gabassi, Audrey, Genin, Michèle, Beniguel, Lydie, Ghosn, Jade, de Lamballerie, Xavier, El Mouhebb, Mayssam, Costagliola, Dominique, Carrat, Fabrice, Molina, Jean Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047207/
https://www.ncbi.nlm.nih.gov/pubmed/35791355
http://dx.doi.org/10.1093/ofid/ofac188
_version_ 1784695678782406656
author Delaugerre, Constance
Assoumou, Lambert
Maylin, Sarah
Minier, Marine
Gabassi, Audrey
Genin, Michèle
Beniguel, Lydie
Ghosn, Jade
de Lamballerie, Xavier
El Mouhebb, Mayssam
Costagliola, Dominique
Carrat, Fabrice
Molina, Jean Michel
author_facet Delaugerre, Constance
Assoumou, Lambert
Maylin, Sarah
Minier, Marine
Gabassi, Audrey
Genin, Michèle
Beniguel, Lydie
Ghosn, Jade
de Lamballerie, Xavier
El Mouhebb, Mayssam
Costagliola, Dominique
Carrat, Fabrice
Molina, Jean Michel
author_sort Delaugerre, Constance
collection PubMed
description The potential preventive efficacy of tenofovir/emtricitabine on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was assessed in human immunodeficiency virus preexposure prophylaxis (PrEP) users. Prevalence of SARS-CoV-2 immunoglobulin G between May and October 2020 was similar in PrEP users and in a matched population-based cohort, suggesting that tenofovir/emtricitabine has no role in reducing the risk of SARS-CoV-2 acquisition.
format Online
Article
Text
id pubmed-9047207
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-90472072022-04-28 Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Among HIV-Negative Participants Using Tenofovir/Emtricitabine-Based Preexposure Prophylaxis in 2020: A Substudy of the French National Agency for Research on AIDS and Viral Hepatitis PREVENIR and Inserm SAPRIS-Sero Cohorts Delaugerre, Constance Assoumou, Lambert Maylin, Sarah Minier, Marine Gabassi, Audrey Genin, Michèle Beniguel, Lydie Ghosn, Jade de Lamballerie, Xavier El Mouhebb, Mayssam Costagliola, Dominique Carrat, Fabrice Molina, Jean Michel Open Forum Infect Dis Brief Report The potential preventive efficacy of tenofovir/emtricitabine on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was assessed in human immunodeficiency virus preexposure prophylaxis (PrEP) users. Prevalence of SARS-CoV-2 immunoglobulin G between May and October 2020 was similar in PrEP users and in a matched population-based cohort, suggesting that tenofovir/emtricitabine has no role in reducing the risk of SARS-CoV-2 acquisition. Oxford University Press 2022-04-12 /pmc/articles/PMC9047207/ /pubmed/35791355 http://dx.doi.org/10.1093/ofid/ofac188 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Report
Delaugerre, Constance
Assoumou, Lambert
Maylin, Sarah
Minier, Marine
Gabassi, Audrey
Genin, Michèle
Beniguel, Lydie
Ghosn, Jade
de Lamballerie, Xavier
El Mouhebb, Mayssam
Costagliola, Dominique
Carrat, Fabrice
Molina, Jean Michel
Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Among HIV-Negative Participants Using Tenofovir/Emtricitabine-Based Preexposure Prophylaxis in 2020: A Substudy of the French National Agency for Research on AIDS and Viral Hepatitis PREVENIR and Inserm SAPRIS-Sero Cohorts
title Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Among HIV-Negative Participants Using Tenofovir/Emtricitabine-Based Preexposure Prophylaxis in 2020: A Substudy of the French National Agency for Research on AIDS and Viral Hepatitis PREVENIR and Inserm SAPRIS-Sero Cohorts
title_full Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Among HIV-Negative Participants Using Tenofovir/Emtricitabine-Based Preexposure Prophylaxis in 2020: A Substudy of the French National Agency for Research on AIDS and Viral Hepatitis PREVENIR and Inserm SAPRIS-Sero Cohorts
title_fullStr Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Among HIV-Negative Participants Using Tenofovir/Emtricitabine-Based Preexposure Prophylaxis in 2020: A Substudy of the French National Agency for Research on AIDS and Viral Hepatitis PREVENIR and Inserm SAPRIS-Sero Cohorts
title_full_unstemmed Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Among HIV-Negative Participants Using Tenofovir/Emtricitabine-Based Preexposure Prophylaxis in 2020: A Substudy of the French National Agency for Research on AIDS and Viral Hepatitis PREVENIR and Inserm SAPRIS-Sero Cohorts
title_short Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Among HIV-Negative Participants Using Tenofovir/Emtricitabine-Based Preexposure Prophylaxis in 2020: A Substudy of the French National Agency for Research on AIDS and Viral Hepatitis PREVENIR and Inserm SAPRIS-Sero Cohorts
title_sort severe acute respiratory syndrome coronavirus 2 seroprevalence among hiv-negative participants using tenofovir/emtricitabine-based preexposure prophylaxis in 2020: a substudy of the french national agency for research on aids and viral hepatitis prevenir and inserm sapris-sero cohorts
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047207/
https://www.ncbi.nlm.nih.gov/pubmed/35791355
http://dx.doi.org/10.1093/ofid/ofac188
work_keys_str_mv AT delaugerreconstance severeacuterespiratorysyndromecoronavirus2seroprevalenceamonghivnegativeparticipantsusingtenofoviremtricitabinebasedpreexposureprophylaxisin2020asubstudyofthefrenchnationalagencyforresearchonaidsandviralhepatitisprevenirandinsermsaprisserocohorts
AT assoumoulambert severeacuterespiratorysyndromecoronavirus2seroprevalenceamonghivnegativeparticipantsusingtenofoviremtricitabinebasedpreexposureprophylaxisin2020asubstudyofthefrenchnationalagencyforresearchonaidsandviralhepatitisprevenirandinsermsaprisserocohorts
AT maylinsarah severeacuterespiratorysyndromecoronavirus2seroprevalenceamonghivnegativeparticipantsusingtenofoviremtricitabinebasedpreexposureprophylaxisin2020asubstudyofthefrenchnationalagencyforresearchonaidsandviralhepatitisprevenirandinsermsaprisserocohorts
AT miniermarine severeacuterespiratorysyndromecoronavirus2seroprevalenceamonghivnegativeparticipantsusingtenofoviremtricitabinebasedpreexposureprophylaxisin2020asubstudyofthefrenchnationalagencyforresearchonaidsandviralhepatitisprevenirandinsermsaprisserocohorts
AT gabassiaudrey severeacuterespiratorysyndromecoronavirus2seroprevalenceamonghivnegativeparticipantsusingtenofoviremtricitabinebasedpreexposureprophylaxisin2020asubstudyofthefrenchnationalagencyforresearchonaidsandviralhepatitisprevenirandinsermsaprisserocohorts
AT geninmichele severeacuterespiratorysyndromecoronavirus2seroprevalenceamonghivnegativeparticipantsusingtenofoviremtricitabinebasedpreexposureprophylaxisin2020asubstudyofthefrenchnationalagencyforresearchonaidsandviralhepatitisprevenirandinsermsaprisserocohorts
AT beniguellydie severeacuterespiratorysyndromecoronavirus2seroprevalenceamonghivnegativeparticipantsusingtenofoviremtricitabinebasedpreexposureprophylaxisin2020asubstudyofthefrenchnationalagencyforresearchonaidsandviralhepatitisprevenirandinsermsaprisserocohorts
AT ghosnjade severeacuterespiratorysyndromecoronavirus2seroprevalenceamonghivnegativeparticipantsusingtenofoviremtricitabinebasedpreexposureprophylaxisin2020asubstudyofthefrenchnationalagencyforresearchonaidsandviralhepatitisprevenirandinsermsaprisserocohorts
AT delamballeriexavier severeacuterespiratorysyndromecoronavirus2seroprevalenceamonghivnegativeparticipantsusingtenofoviremtricitabinebasedpreexposureprophylaxisin2020asubstudyofthefrenchnationalagencyforresearchonaidsandviralhepatitisprevenirandinsermsaprisserocohorts
AT elmouhebbmayssam severeacuterespiratorysyndromecoronavirus2seroprevalenceamonghivnegativeparticipantsusingtenofoviremtricitabinebasedpreexposureprophylaxisin2020asubstudyofthefrenchnationalagencyforresearchonaidsandviralhepatitisprevenirandinsermsaprisserocohorts
AT costaglioladominique severeacuterespiratorysyndromecoronavirus2seroprevalenceamonghivnegativeparticipantsusingtenofoviremtricitabinebasedpreexposureprophylaxisin2020asubstudyofthefrenchnationalagencyforresearchonaidsandviralhepatitisprevenirandinsermsaprisserocohorts
AT carratfabrice severeacuterespiratorysyndromecoronavirus2seroprevalenceamonghivnegativeparticipantsusingtenofoviremtricitabinebasedpreexposureprophylaxisin2020asubstudyofthefrenchnationalagencyforresearchonaidsandviralhepatitisprevenirandinsermsaprisserocohorts
AT molinajeanmichel severeacuterespiratorysyndromecoronavirus2seroprevalenceamonghivnegativeparticipantsusingtenofoviremtricitabinebasedpreexposureprophylaxisin2020asubstudyofthefrenchnationalagencyforresearchonaidsandviralhepatitisprevenirandinsermsaprisserocohorts
AT severeacuterespiratorysyndromecoronavirus2seroprevalenceamonghivnegativeparticipantsusingtenofoviremtricitabinebasedpreexposureprophylaxisin2020asubstudyofthefrenchnationalagencyforresearchonaidsandviralhepatitisprevenirandinsermsaprisserocohorts

Ejemplares similares